- Home
- DMAC vs LFCR Comparison
DMAC vs LFCR Comparison
Compare DMAC & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- LFCR
- Stock Information
- Founded
- DMAC 2000
- LFCR 1986
- Country
- DMAC United States
- LFCR United States
- Employees
- DMAC N/A
- LFCR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- LFCR Health Care
- Exchange
- DMAC Nasdaq
- LFCR Nasdaq
- Market Cap
- DMAC 260.0M
- LFCR 308.8M
- IPO Year
- DMAC N/A
- LFCR N/A
- Fundamental
- Price
- DMAC $4.76
- LFCR $7.29
- Analyst Decision
- DMAC Strong Buy
- LFCR Buy
- Analyst Count
- DMAC 4
- LFCR 4
- Target Price
- DMAC $10.75
- LFCR $8.00
- AVG Volume (30 Days)
- DMAC 353.4K
- LFCR 158.0K
- Earning Date
- DMAC 08-06-2025
- LFCR 08-25-2025
- Dividend Yield
- DMAC N/A
- LFCR N/A
- EPS Growth
- DMAC N/A
- LFCR N/A
- EPS
- DMAC N/A
- LFCR N/A
- Revenue
- DMAC N/A
- LFCR $130,309,000.00
- Revenue This Year
- DMAC N/A
- LFCR $1.64
- Revenue Next Year
- DMAC N/A
- LFCR $2.91
- P/E Ratio
- DMAC N/A
- LFCR N/A
- Revenue Growth
- DMAC N/A
- LFCR 7.23
- 52 Week Low
- DMAC $3.19
- LFCR $3.68
- 52 Week High
- DMAC $6.82
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- DMAC 64.04
- LFCR 46.96
- Support Level
- DMAC $4.81
- LFCR $7.15
- Resistance Level
- DMAC $5.60
- LFCR $7.61
- Average True Range (ATR)
- DMAC 0.45
- LFCR 0.36
- MACD
- DMAC 0.11
- LFCR -0.10
- Stochastic Oscillator
- DMAC 67.90
- LFCR 19.12
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.